Abstract:Abstract Background In the population of postmenopausal patients with major depressive disorder (MDD), the superiority of serotonin-norepinephrine reuptake inhibitors (SNRIs) over selective serotonin reuptake inhibitors (SSRIs) has not yet been definitively proven. Consequently, a direct comparison of the efficacy of SSRIs and SNRIs in the treatment of postmenopausal depression could provide relevant data. The aim of this study was to compare the efficacy and safety of venlafaxine vs. fluoxetine in the treatment of postmenopausal MDD. Methods This was an 8-week, multicenter, randomized, single-blind, active-controlled trial conducted at a psychiatric hospital (Beijing Anding Hospital) and a general hospital (Beijing Chaoyang Hospital) between April 2013 and September 2017. The primary outcome measure was improving depressive symptoms (Hamilton Depression Rating Scale (HAMD-24) score). The secondary outcomes included the change of HAMD-24 anxiety/somatization factor score and Clinical Global Impressions-Improvement (CGI-I) response rate. Safety was assessed by treatment-emergent adverse events (TEAEs) and laboratory tests. Efficacy was analyzed by using the full analysis set (FAS) following the modified intention-to-treat (mITT) principle. The primary endpoint measurements were analyzed using a mixed-effect model for repeated measures (MMRM) model with patients as a random-effect factor, treatment group as the independent variable, time as a repeated measure, and baseline covariates, using a first-order ante dependence covariance matrix. Results A total of 184 women were randomized. The full analysis set (FAS) included 172 patients (venlafaxine, n = 82; fluoxetine, n = 90). Over the 8-week study period, the reduction in HAMD-24 scores was significant ( P < 0.001) in both groups, while a significantly greater decline from baseline was observed in the venlafaxine group compared with the fluoxetine group (least-squares mean difference [95% CI]: − 2.22 [− 7.08, − 0.41]), P = 0.001). The baseline-to-week-8 least-squares mean change of the anxiety/somatization factor scores, CGI-I response rate were greater in the venlafaxine group than in the fluoxetine group (all P < 0.05). The most frequent TEAEs (≥5%) in both groups were nausea, somnolence, dizziness, headache, and dry mouth. There was no significant difference in the incidence of adverse events between the two groups. Conclusion Venlafaxine was well tolerated and compared to fluoxetine, it led to a greater improvement in the treatment of postmenopausal MDD. Trial registration Clinical Trials. gov #NCT01824433 . The trial was registered on April 4, 2013.

A randomized clinical trial comparing two two-phase treatment strategies for in-patients with severe depression

Treatment of Depressive Outpatient with Venlafaxine:An Open Clinical Trial

A Randomized Controlled Clinical Trial of the Combination of Venlafaxine for Treatment-Resistant Depression

Outcome of a three-phase treatment algorithm for inpatients with melancholic depression

Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate

Comparisons of the Efficacy and Tolerability of Extended-Release Venlafaxine, Mirtazapine, and Paroxetine in Treatment-Resistant Depression: a Double-Blind, Randomized Pilot Study in a Chinese Population.

Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression--The EMC trial

ComParison of different treatment regimens for refractory dePression efficacy

Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study

Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study

Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial

A Randomized Double-Blind Controlled Clinical Trail of Venlafaxine Sustained Release Tablets Vs.sustained-Release Capsules in Treatment of Major Depression Disorder

A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression

A parallel control study of venlafaxine and fluoxertine in first-episode patients with depression

Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors

Pharmacoeconomic Comparisons of Venlafaxine and Mirtazapine in Patients with Treatment-Resistant Major Depression

Comparative study of Duloxetine combined with Mirtazapine, Venlafaxine combined with Mirtazapine in treatment of refractory depression

A Novel Strategy for Continuation ECT in Geriatric Depression: Phase 2 of the PRIDE Study

Venlafaxine in treating 62 patients with depression: a multicenter open trial

Efficacy of venlafaxine in treatment of selective serotonin reuptake inhibitors non-responders with major depressive disorder

Lithium augmentation in venlafaxine non-responders: an open study